Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-25-006159
Filing Date
2025-08-14
Accepted
2025-08-14 16:01:49
Documents
65
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR JUN 2025 actuate_i10q-063025.htm   iXBRL 10-Q 767899
2 CERTIFICATION actuate_ex3101.htm EX-31.1 7602
3 CERTIFICATION actuate_ex3102.htm EX-31.2 7628
4 CERTIFICATION actuate_ex3201.htm EX-32.1 6092
10 GRAPHIC image_001.jpg GRAPHIC 1129
  Complete submission text file 0001683168-25-006159.txt   4129173

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE actu-20250630.xsd EX-101.SCH 35771
6 XBRL CALCULATION FILE actu-20250630_cal.xml EX-101.CAL 41307
7 XBRL DEFINITION FILE actu-20250630_def.xml EX-101.DEF 169635
8 XBRL LABEL FILE actu-20250630_lab.xml EX-101.LAB 287998
9 XBRL PRESENTATION FILE actu-20250630_pre.xml EX-101.PRE 279380
67 EXTRACTED XBRL INSTANCE DOCUMENT actuate_i10q-063025_htm.xml XML 479859
Mailing Address 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107
Business Address 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 847-986-4190
ACTUATE THERAPEUTICS, INC. (Filer) CIK: 0001652935 (see all company filings)

EIN.: 473044785 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42139 | Film No.: 251218491
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)